Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- (-) Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- (-) Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- (-) Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Audience
Display Only
Showing 108 Results
Health Plan Use of Patient Data: From the Routine to the Transformational
As the abundance and variety of patient data elements and sources continue to grow, health plans seek opportunities to deepen insights from multiple sources of patient data to shape care delivery,…
Improving Oncology Quality Measurement in Accountable Care
This comprehensive white paper from the National Pharmaceutical Council and Discern Health identified gaps in accountable care quality measure sets for cancer, which can lead to missed opportunities…
Is Real World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Payers infrequently used real-world evidence (RWE), or information on how treatments work in the real world, to guide their medication coverage and reimbursement decisions, according to research…
Do Payers Use Real-World Evidence to Guide Their Coverage and Reimbursement Decisions?
Payers infrequently used real-world evidence (RWE), or information on how treatments work in the real world, to guide their medication coverage and reimbursement decisions, according to new research…
Value Assessment Frameworks: Are They Up To The Challenge?
In this article published on the Health Affairs Blog, NPC researchers Dr. Robert Dubois and Kimberly Westrich ask: Are value assessment frameworks ready to compare the health and economic impacts of…
The Evolution of Value Assessment
A Health Affairs Blog post by NPC Chief Science Officer Robert Dubois, MD, PhD, and Vice President for Health Services Research Kimberly Westrich, MA, identified several key considerations that could…
Comparison of Value Framework Assessments for Multiple Myeloma
In this NPC-funded study conducted by the Lewin Group, four existing value assessment frameworks were compared head to head to understand how each framework would approach the same condition,…
How Is the Multiple Sclerosis Community Engaging on Value Assessment?
NPC President Dan Leonard caught up this week for a Q&A with Lisa Skutnik, President of the MS Coalition, to discuss how the value of multiple sclerosis (MS) treatments is being assessed,…
Improving Oncology Quality Measurement in Accountable Care: Filling Gaps with Cross-Cutting Measures
According to a study, gaps in the quality measures used by accountable care programs to assess cancer care may obscure problems in care delivery and lead to missed opportunities for improvement of…
How Are Stakeholder Views Incorporated into Value Assessment Frameworks? Watch NPC's New Video
NPC's animated informational video explains how different organizations are trying to consider patient viewpoints through the development of value assessment frameworks.
Assessing Value: Promise and Pitfalls Conference Summary Report
At NPC's conference, Assessing Value: Promise and Pitfalls, top experts in their fields united to discuss value assessment as it impacts payers, patients, providers and pharmaceutical innovators.
Engaging With ICER: National Psoriasis Foundation Opens Up on Value Assessment
NPC President Dan Leonard chatted with Leah Howard, Vice President of Government Relations and Advocacy, National Psoriasis Foundation, about value assessment frameworks and how her organization is…
Data, Data Everywhere, But Access Remains a Big Issue for Researchers
This study captures the policy inconsistencies and hurdles that can hinder use of publicly funded federal and state datasets for researchers. These limitations can make it harder to conduct high…
Why Is Broader Access to Publicly Funded Data Important?
This infographic illustrates the policy inconsistencies and hurdles that can hinder use of publicly funded federal and state datasets for researchers.
Guiding Practices for Patient-Centered Value Assessment
In 2016, NP developed Guiding Practices for Patient-Centered Value Assessment that included 28 specific elements, which are broken out into six key aspects of value assessments: the assessment…
Developing Evidence that is Fit for Purpose: A Framework for Payer and Research Dialogue
A study published in the September 2015 issue of The American Journal of Managed Care introduces a framework developed by the National Pharmaceutical Council (NPC) and AcademyHealth that could help…
Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion Test Assessment Tool
This peer-reviewed study examined some of the barriers to incorporating a Companion Diagnostic Test (CDT) into drug treatment decisions and outlined a framework to assist managed care…
When Does FDAMA Section 114 Apply? Ten Case Studies
There is hesitation to disseminate comparative effectiveness research because of ambiguities in the law that was established to help biopharmaceutical companies engage health plans around real-world…
Accountable Care Measures for High-Cost Specialty Care and Innovative Treatment
This comprehensive white paper from the National Pharmaceutical Council and Discern Health identified gaps in accountable care quality measure sets for cancer, which can lead to missed opportunities…
Individual Treatment Effects: Implications for Research, Clinical Practice, and Policy
This research outlines a framework and policy considerations to help health care stakeholders understand when it is important take patients’ individual treatment responses into account when making…